Evidence map›Paper›PMID 31854153›Full record

ArticleKorean journal of radiology2019

US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population.

Hyun Kyung Lim, Se Jin Cho, Jung Hwan Baek, Kang Dae Lee, Chang Woo Son, Jung Min Son, Seon Mi Baek

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Korean journal of radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Ablative Technologies for Thyroid Nodules: A Health Technology Assessment.Ontario health technology assessment series · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Updates in ultrasound-guided musculoskeletal interventions.The British journal of radiology · 2026
    Review
  12. Article
  13. Ablative Therapies in Low-Risk Thyroid Cancer.Annals of surgical oncology · 2025
    Review
  14. Article
  15. Landmark Studies in Differentiated Thyroid Cancer.Annals of surgical oncology · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Hyun Kyung Lim *Department of Radiology, Soonchunhyang University Seoul Hospital, Seoul, Korea.ORCID 0000-0003-2319-3135
Se Jin Cho *Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0001-6450-7554
Jung Hwan BaekDepartment of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Kang Dae LeeDepartment of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine, Busan, Korea.
Chang Woo SonDepartment of Radiology, Korean Association of Health Promotion, Busan, Korea.
Jung Min SonDepartment of Radiology, Haeundae Sharing and Happiness Hospital, Busan, Korea.
Seon Mi BaekDepartment of Radiology, Haeundae Sharing and Happiness Hospital, Busan, Korea. snhbsm@naver.com.ORCID 0000-0001-8075-0730

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and safety of radiofrequency ablation (RFA) for low-risk papillary thyroid microcarcinoma (PTMC) in a large population. MATERIALS AND

methodsCases of 152 biopsy-proven PTMCs from 133 patients who had undergone RFA for PTMC between May 2008 and January 2017 were included in this study. All patients were either of high surgical risk or refused to undergo surgery. They were followed up for at least 6 months after initial RFA. Ultrasonography (US) and computed tomography were performed to evaluate the PTMC and the presence of neck metastasis before treatment. RFA was conducted using an internally cooled thyroid-dedicated electrode system. Follow-up US was performed at 1 week, and 2, 6, and 12 months, after the initial RFA, and then at every 6-12 months. We evaluated serial changes of ablated tumors, newly developed cancers, lymph node (LN) or distant metastasis and complications.

resultsComplete disappearance was found in 91.4% (139/152) of ablated tumors. Among the 13 tumors in patients who did not show complete disappearance, no tumor displayed any regrowth of the residual ablated lesion during the follow-up period. The mean follow-up period was 39 months. During the follow-up period, there were no local recurrence, no LN or distant metastasis, and no newly developed thyroid cancers. No patients were referred to surgery. The overall complication rate was 3% (4/133) of patients, including one voice change. There were no life-threatening complications or procedure-related deaths.

conclusionOur results suggest that RFA is an effective and safe option for treating low-risk PTMC patients who are of high surgical risk or refuse surgery.

Indexed as

AdultAgedAged, 80 and overCarcinoma, PapillaryCatheter AblationFemaleHematomaHumansMaleMiddle AgedPostoperative ComplicationsRiskThyroid NeoplasmsTomography, X-Ray ComputedTreatment OutcomeUltrasonographyPapillary thyroid microcarcinomaRadiofrequency ablationUltrasonography

Identifiers

PMID31854153
PMCPMC6923213

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.